| 영문 | protein | 한글 | 단백질 |
|---|---|---|---|
| 설명 | 탄소, 수소, 산소, 질소, 황을 함유하고 있는 유기화합물로, 모든 세포의 원형질을 이루고 있는 기본 구성물질이다. 단백질은 그 단위인 아미노산들이 펩티드결합에 의해 결합되어 있으며, 보통 20개의 아미노산들이 다른 순서와 조성을 가지고 배열되어, 독특한 하나의 단백질을 형성하게 된다. |
||
| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| PS | pacemaker syndrome; paired stimulation; paradoxical sleep; paraspinal; parasympathetic; Parkinson sy... |
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
| FSR | Fractional protein synthesis rate |
|---|---|
| PSR | Protein Synthesis Rate |
| PS | Protein synthesis |
| ASR | Absolute synthesis rate |
| NOS | nitric oxide synthesis |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| cell-free protein synthesis | <technique> An in vitro method to make proteins, using amino acids, the mRNA corresponding to the protein to be made, and a cell-free extract (the contents of a cell after removal of the cell wall and/or outer cell membranes) for other needed components and enzymes. (26 Mar 1998) |
|---|---|
| protein synthesis | The process in which individual amino acids, whether of exogenous or endogenous origin, are connected to each other in peptide linkage in a specific order dictated by the sequence of nucleotides in DNA; this governing sequence is conveyed to the synthesizing apparatus in the ribosomes by mRNA, formed by base-pairing on the DNA template. (05 Mar 2000) |
| protein synthesis inhibitor | Compounds which inhibit the synthesis of proteins. They are usually antibiotics or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the the a site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (12 Dec 1998) |
| vectorial synthesis | <cell biology> Term usually applied to the mode of synthesis of proteins destined for export from the cell. As the protein is made it moves (vectorially) through the membrane of the rough endoplasmic reticulum, to which the ribosome is attached and into the cisternal space. (06 Mar 2000) |
| gene synthesis | <molecular biology> The complete synthesis of a gene using a DNA synthesiser (gene machine), or the assembly of oligonucleotides so synthesised into a synthetic gene, as opposed to cloning. (14 Nov 1997) |
| cellular immunodeficiency with abnormal immunoglobulin synthesis | An ill-defined group of sporadic disorders of unknown cause, occurring in both males and females and associated with recurrent bacterial, fungal, protozoal, and viral infections; there is thymic hypoplasia with depressed cellular (T-lymphocyte) immunity combined with defective humoral (B-lymphocyte) immunity, although immunoglobulin levels may be normal. Synonym: Nezelof syndrome, Nezelof type of thymic alymphoplasia. (05 Mar 2000) |
| Merrifield synthesis | The synthesis of peptides and proteins via an automated system on carrier polymers. (05 Mar 2000) |
| chiral synthesis | <chemistry> The production of chiral compounds in only one enantiomer, or handedness. (See chirality) (05 Jan 1998) |
| coordinated enzyme synthesis | The regulatory mechanism where an entire group of different enzymes, all of which play a part in the same metabolic process, is synthesised at the same time. This comes about because the chemical signal to begin synthesis of each enzyme is the same for all of them. (09 Oct 1997) |
| nucleic acid synthesis inhibitors | Compounds that inhibit cell production of DNA or RNA. (12 Dec 1998) |
| synthesis | 1. <biochemistry, chemistry> The artificial building up of a chemical compound, by the union of its elements or from other suitable starting materials. 2. <psychiatry> The integration of the various elements of the personality, the opposite of analysis. Origin: Gr. = a putting together, composition (19 Jan 1998) |
| synthesis of continuity | Healing of the edges of a wound or fracture. (05 Mar 2000) |
| synthesis period | The period of the cell cycle when there is synthesis of DNA and histone; it occurs between Gap1 and Gap2. Synonym: S phase. (05 Mar 2000) |
| DNA synthesis | <molecular biology> The linking together of nucleotides (as deoxyribonucleotide triphosphates) to form DNA. In vivo, most synthesis is DNA replication, but incorporation of precursors also occurs in repair. In the special case of retroviruses, DNA synthesis is directed by an RNA template (see reverse transcriptase). (18 Nov 1997) |
| enzymatic synthesis | Synthesis by enzymes. See: biosynthesis. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|